Abstract library

110 results for "non-functioning".
#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#3014 The Number of Positive Nodes Accurately Predicts Recurrence after Distal Pancreatectomy for Nonfunctioning Neuroendocrine Neoplasms
Introduction: The most appropriate staging system of metastatic lymph nodes (N) for resected pancreatic neuroendocrine tumors (PanNETs) remains unclear, especially regarding those resected by distal pancreatectomy (DP).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr. Giovanni Guarneri
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz
#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET
Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Sebastian Krug
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features
Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Emilia Alors-Pérez
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi